Exelixis Inc Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Exelixis Inc (EXEL) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $611.07 million as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2026-08-05
- 2026-07-03: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $611.07M.
- 2026-04-03: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $616.80M.
- 2026-01-02: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $691.41M.
- 2025-10-03: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $680.64M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One as first filed |
|---|---|---|
| 2026-07-03 | $611.07M 10-Q · filed 2026-08-05 | |
| 2026-04-03 | $616.80M 10-Q · filed 2026-05-05 | |
| 2026-01-02 | $691.41M 10-Q · filed 2026-08-05 | |
| 2025-10-03 | $680.64M 10-Q · filed 2025-11-04 | |
| 2025-07-04 | $673.98M 10-Q · filed 2025-07-28 | |
| 2025-04-04 | $840.25M 10-Q · filed 2025-05-13 | |
| 2025-01-03 | $888.36M 10-K · filed 2026-02-10 | |
| 2024-09-27 | $966.16M 10-Q · filed 2024-10-29 | |
| 2024-06-28 | $844.82M 10-Q · filed 2024-08-06 | |
| 2024-03-29 | $767.83M 10-Q · filed 2024-04-30 | |
| 2023-12-29 | $768.71M 10-K · filed 2025-02-11 | |
| 2023-09-29 | $836.52M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $1.04B 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $1.07B 10-Q · filed 2023-05-09 | |
| 2022-12-30 | $1.11B 10-K · filed 2024-02-06 | |
| 2022-09-30 | $1.26B 10-Q · filed 2022-11-01 | |
| 2022-07-01 | $1.25B 10-Q · filed 2022-08-09 | |
| 2022-04-01 | $1.29B 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.17B 10-K · filed 2023-02-07 | |
| 2021-10-01 | $1.10B 10-Q · filed 2021-11-02 | |
| 2021-07-02 | $1.02B 10-Q · filed 2021-08-05 | |
| 2021-04-02 | $1.02B 10-Q · filed 2021-05-06 | |
| 2021-01-01 | $1.03B 10-K · filed 2022-02-18 | |
| 2020-10-02 | $993.21M 10-Q · filed 2020-11-05 | |
| 2020-07-03 | $720.09M 10-Q · filed 2020-08-06 | |
| 2020-04-03 | $641.07M 10-Q · filed 2020-05-05 | |
| 2020-01-03 | $789.91M 10-K · filed 2021-02-11 | |
| 2019-09-27 | $743.77M 10-Q · filed 2019-10-30 | |
| 2019-06-28 | $809.61M 10-Q · filed 2019-07-31 | |
| 2019-03-29 | $784.43M 10-Q · filed 2019-05-01 | |
| 2018-12-28 | $626.71M 10-K · filed 2020-02-25 | $674.46M 10-K · filed 2019-02-22 |
| 2018-09-28 | $635.21M 10-Q · filed 2018-11-01 | |
| 2018-06-29 | $500.48M 10-Q · filed 2018-08-01 | |
| 2018-03-30 | $410.06M 10-Q · filed 2018-05-02 | |
| 2017-12-29 | $377.15M 10-K · filed 2019-02-22 | |
| 2017-09-30 | $362.77M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $343.81M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $411.60M 10-Q · filed 2017-05-01 | |
| 2016-12-30 | $404.37M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $310.24M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $323.06M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $402.00M 10-Q · filed 2016-05-04 | |
| 2015-09-30 | $250.68M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $163.57M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $191.20M 10-Q · filed 2015-04-30 | |
| 2014-09-30 | $267.95M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $302.96M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $358.60M 10-Q · filed 2014-05-01 | |
| 2012-09-30 | $555.90M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $292.17M 10-Q · filed 2012-08-02 | |
| 2011-12-31 | $259.08M 10-Q · filed 2012-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |